Monte Rosa Therapeutics, Inc.
GLUE
$3.70
-$0.34-8.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 14,889.38% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14,889.38% | -- | -- | -- | -- |
| Cost of Revenue | 20.23% | -18.43% | 0.20% | 110.95% | 110.95% |
| Gross Profit | 291.60% | 117.48% | 29.23% | -87.49% | -106.61% |
| SG&A Expenses | 4.83% | 9.51% | -8.91% | 0.30% | 2.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.41% | 9.37% | 2.14% | 9.71% | 18.57% |
| Operating Income | 98.52% | 43.40% | 8.48% | -5.36% | -17.70% |
| Income Before Tax | 107.02% | 48.06% | 10.20% | -3.84% | -15.65% |
| Income Tax Expenses | 685.99% | 660.36% | 6.67% | 154.21% | -- |
| Earnings from Continuing Operations | 104.55% | 46.29% | 10.15% | -4.07% | -16.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 104.55% | 46.29% | 10.15% | -4.07% | -16.02% |
| EBIT | 98.52% | 43.40% | 8.48% | -5.36% | -17.70% |
| EBITDA | 104.48% | 46.76% | 9.03% | -5.19% | -18.34% |
| EPS Basic | 100.71% | 59.01% | 31.92% | 12.96% | -3.98% |
| Normalized Basic EPS | 102.30% | 60.09% | 31.88% | 13.06% | -3.80% |
| EPS Diluted | 100.68% | 59.01% | 31.92% | 12.96% | -3.98% |
| Normalized Diluted EPS | 102.08% | 60.09% | 31.88% | 13.06% | -3.80% |
| Average Basic Shares Outstanding | 46.77% | 43.79% | 36.88% | 22.49% | 12.88% |
| Average Diluted Shares Outstanding | 47.15% | 43.79% | 36.88% | 22.49% | 12.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |